---
name: academic-debate
description: |
  å­¸è¡“è¾¯è«–èˆ‡è§€é»æ¯”è¼ƒæ¡†æ¶ã€‚
  LOAD THIS SKILL WHEN: debateã€è¾¯è«–ã€pro/conã€æ­£åæ–¹ã€devil's advocateã€æŒ‘æˆ°å‡è¨­ã€counter-argumentã€åé§ã€compare viewpointsã€æ¯”è¼ƒè§€é»ã€challengeã€è³ªç–‘
  CAPABILITIES: ç´”æŒ‡ä»¤æŠ€èƒ½ï¼Œä¸éœ€è¦å°ˆå±¬ MCP toolã€‚åˆ©ç”¨ LLM æ¨ç†èƒ½åŠ› + ç¾æœ‰ tools (read_draft, search_local_references) å®Œæˆåˆ†æã€‚
---

# å­¸è¡“è¾¯è«–èˆ‡è§€é»æ¯”è¼ƒæŠ€èƒ½

## è¨­è¨ˆæ„åœ–

> **ç‚ºä»€éº¼é€™ä¸æ˜¯ MCP Toolï¼Ÿ**
> è¾¯è«–æ¡†æ¶ã€åèª¤åˆ†æã€è§€é»æ¯”è¼ƒæ˜¯ã€Œçµæ§‹åŒ–æ€è€ƒã€ï¼ŒLLM æœ¬èº«å°±èƒ½åšå¾—æ¯” hard-coded æ¨¡æ¿æ›´å¥½ã€‚
> é€™è£¡æä¾›çš„æ˜¯ã€Œdomain knowledgeã€è®“ LLM çŸ¥é“å¦‚ä½•ç³»çµ±æ€§åœ°æ§‹å»ºå­¸è¡“è¾¯è«–ã€‚

---

## é©ç”¨æƒ…å¢ƒ

| è§¸ç™¼èª | æ“ä½œ |
|--------|------|
| ã€Œå¹«æˆ‘è¾¯è«– X vs Yã€ | â†’ ä½¿ç”¨ Debate Framework |
| ã€ŒæŒ‘æˆ°ä¸€ä¸‹é€™å€‹è§€é»ã€ | â†’ ä½¿ç”¨ Devil's Advocate Framework |
| ã€Œæ¯”è¼ƒé€™å¹¾ç¨®æ–¹æ³•ã€ | â†’ ä½¿ç”¨ Viewpoint Comparison Framework |
| ã€Œé€™å€‹ claim ç«™å¾—ä½è…³å—ã€ | â†’ ä½¿ç”¨ Devil's Advocate Framework |

---

## å¯æ­é…çš„ MCP Tools

| å·¥å…· | ç”¨é€” |
|------|------|
| `read_draft` | è®€å–è‰ç¨¿ç²å–éœ€è¦è¾¯è«–/æŒ‘æˆ°çš„å…§å®¹ |
| `search_local_references` | æœå°‹å·²å­˜æ–‡ç»ä½è­‰æ­£åæ–¹è§€é» |
| `list_saved_references` | åˆ—å‡ºå¯ç”¨å¼•ç”¨ |
| `mcp_cgu_deep_think` | æ·±åº¦åˆ†æå¼±é» |
| `mcp_cgu_spark_collision` | ç¢°æ’æ­£åè§€é»ç”¢ç”Ÿæ–°æ´è¦‹ |

---

## Framework 1: Academic Debate (é›™æ–¹è¾¯è«–)

**ç›®æ¨™**ï¼šé‡å°ä¸€å€‹ç ”ç©¶è­°é¡Œï¼Œçµæ§‹åŒ–æ­£åæ–¹è«–é»

### è¼¸å‡ºçµæ§‹

```markdown
# ğŸ”¬ Academic Debate: {topic}

**Context:** {ç ”ç©¶èƒŒæ™¯}
**Study Type:** {åµæ¸¬åˆ°çš„ç ”ç©¶é¡å‹}

---

## âœ… Position A: {supporting_position}

### Supporting Arguments
ï¼ˆæŒ‰ç…§è­‰æ“šç­‰ç´šæ’åˆ—ï¼Œæœ€å¼·çš„æ”¾æœ€å‰é¢ï¼‰

| # | Argument | Evidence Level | Source |
|---|----------|---------------|--------|
| 1 | [å…·é«”è«–é»] | [è­‰æ“šç­‰ç´š] | [[citation]] |

## âŒ Position B: {opposing_position}

### Counter-Arguments
ï¼ˆåŒæ¨£æŒ‰ç…§è­‰æ“šç­‰ç´šæ’åˆ—ï¼‰

## âš–ï¸ Methodological Considerations ({study_type})

æ ¹æ“šç ”ç©¶é¡å‹åˆ—å‡ºç›¸é—œåèª¤ï¼ˆè¦‹ä¸‹æ–¹åèª¤æ¸…å–®ï¼‰

## ğŸ”„ Synthesis for Discussion Section

### Areas of Agreement
### Key Disagreements
### Clinical Bottom Line
```

---

## Framework 2: Devil's Advocate (é­”é¬¼ä»£è¨€äºº)

**ç›®æ¨™**ï¼šç³»çµ±æ€§æŒ‘æˆ°ä¸€å€‹ç ”ç©¶ä¸»å¼µçš„å¼±é»

### è¼¸å‡ºçµæ§‹

```markdown
# ğŸ˜ˆ Devil's Advocate Analysis

**Claim:** {è¦æŒ‘æˆ°çš„ä¸»å¼µ}
**Supporting Evidence:** {ç¾æœ‰æ”¯æŒè­‰æ“š}
**Study Type:** {ç ”ç©¶é¡å‹}

---

## 1. Methodological Challenges ({study_type})
ï¼ˆæ ¹æ“šç ”ç©¶é¡å‹é¸æ“‡ç›¸é—œåèª¤ï¼Œè¦‹ä¸‹æ–¹åèª¤æ¸…å–®ï¼‰

## 2. Statistical Challenges
- Multiple comparisons / Type I error
- Effect size (clinical significance vs statistical significance)
- Confidence interval width
- Missing data handling (MCAR/MAR/MNAR)
- Power / sample size adequacy

## 3. Generalizability Concerns
- Population: çµæœèƒ½æ¨å»£å—ï¼Ÿ
- Setting: å–®ä¸­å¿ƒ vs å¤šä¸­å¿ƒï¼Ÿ
- Timeframe: çŸ­æœŸ â†’ é•·æœŸï¼Ÿ
- Intervention fidelity: èƒ½è¢«é‡è¤‡å—ï¼Ÿ

## 4. Alternative Explanations
- Confounding?
- Reverse causation?
- Temporal trends?
- Hawthorne/placebo effect?

## 5. Likely Reviewer Questions
ï¼ˆåŸºæ–¼ Study Type ç”¢å‡ºæœ€å¯èƒ½è¢« reviewer å•çš„å•é¡Œï¼‰

## ğŸ’ª Strengthening Recommendations
1. Address strongest counter-argument in Discussion
2. Add sensitivity/subgroup analyses
3. Acknowledge limitations proactively
4. Cite supportive systematic reviews
5. Frame clinical implications conservatively
```

---

## Framework 3: Viewpoint Comparison (è§€é»æ¯”è¼ƒ)

**ç›®æ¨™**ï¼šç³»çµ±æ€§æ¯”è¼ƒå¤šå€‹ç†è«–/æ–¹æ³•è§€é»

### è¼¸å‡ºçµæ§‹

```markdown
# ğŸ”€ Viewpoint Comparison: {topic}

## Summary Comparison

| Criterion | Viewpoint A | Viewpoint B | ... |
|-----------|-------------|-------------|-----|
| Evidence Base | [analysis] | [analysis] | |
| Theoretical Foundation | ... | ... | |
| Clinical Applicability | ... | ... | |
| Patient Safety | ... | ... | |
| Cost-Effectiveness | ... | ... | |
| Current Guidelines | ... | ... | |
| Limitations | ... | ... | |

## Viewpoint 1: {name}
- Core Premise
- Key Proponents
- Best Evidence
- Strengths
- Weaknesses

(repeat for each viewpoint)

## ğŸ”— Implications for Your Research
### Points of Convergence
### Points of Divergence
### Recommended Position
```

### é è¨­æ¯”è¼ƒç¶­åº¦

å¦‚æœç”¨æˆ¶æ²’æœ‰æŒ‡å®šæ¯”è¼ƒç¶­åº¦ï¼Œä½¿ç”¨ä»¥ä¸‹é è¨­ï¼š
1. Evidence Baseï¼ˆè­‰æ“šåŸºç¤ï¼‰
2. Theoretical Foundationï¼ˆç†è«–åŸºç¤ï¼‰
3. Clinical Applicabilityï¼ˆè‡¨åºŠé©ç”¨æ€§ï¼‰
4. Patient Safetyï¼ˆç—…äººå®‰å…¨ï¼‰
5. Cost-Effectivenessï¼ˆæˆæœ¬æ•ˆç›Šï¼‰
6. Current Guidelinesï¼ˆç›®å‰æŒ‡å¼•ï¼‰
7. Limitationsï¼ˆé™åˆ¶ï¼‰

---

## ğŸ§  Domain Knowledge: Evidence Hierarchy

Agent åœ¨æ§‹å»ºè¾¯è«–æ™‚ï¼ŒæŒ‰æ­¤ç­‰ç´šæ’åˆ—è­‰æ“šï¼š

1. **Systematic Review / Meta-Analysis** â€” æœ€é«˜ç­‰ç´š
2. **Randomized Controlled Trial (RCT)**
3. **Cohort Study (Prospective)**
4. **Case-Control Study**
5. **Cross-Sectional Study**
6. **Case Series / Case Report**
7. **Expert Opinion / Editorial** â€” æœ€ä½ç­‰ç´š

---

## ğŸ§  Domain Knowledge: Study-Type-Specific Biases

### RCT
- Selection bias (randomization failure)
- Performance bias (blinding issues)
- Detection bias (outcome assessment)
- Attrition bias (dropouts)
- Reporting bias (selective outcome reporting)

### Cohort Study
- Selection bias (non-random sampling)
- Confounding (unmeasured variables)
- Information bias (measurement error)
- Loss to follow-up
- Healthy worker effect

### Case-Control Study
- Recall bias
- Selection bias (control selection)
- Confounding
- Misclassification bias
- Temporal ambiguity

### Cross-Sectional Study
- Cannot establish temporality
- Prevalence-incidence bias
- Non-response bias
- Information bias
- Confounding

### Retrospective Study
- Information bias (records quality)
- Selection bias (survivorship)
- Confounding
- Missing data
- Temporal bias

---

## ğŸ” Study Type Detection

æ ¹æ“šæ–‡å­—å…§å®¹è‡ªå‹•åµæ¸¬ç ”ç©¶é¡å‹ï¼Œç”¨ä»¥ä¸‹é—œéµå­—ï¼š

| é—œéµå­— | ç ”ç©¶é¡å‹ |
|--------|----------|
| randomized, RCT, blinded, placebo | RCT |
| cohort, prospective, follow-up, incidence | Cohort |
| case-control, odds ratio, exposure | Case-Control |
| cross-sectional, prevalence, survey | Cross-Sectional |
| retrospective, chart review, medical records | Retrospective |

---

## âš ï¸ ä½¿ç”¨åŸå‰‡

1. **æ°¸é åŸºæ–¼è­‰æ“š** â€” ä¸è¦ç©ºæ³›ç™¼è¨€ï¼Œå¼•ç”¨å·²å­˜æ–‡ç»
2. **å¹³è¡¡å‘ˆç¾** â€” å³ä½¿ä¸€æ–¹æ˜é¡¯è¼ƒå¼·ï¼Œä¹Ÿè¦å…¬å¹³å‘ˆç¾å¦ä¸€æ–¹
3. **æ¨™æ˜ç ”ç©¶é¡å‹** â€” åèª¤åˆ†æå¿…é ˆå°æ‡‰æ­£ç¢ºçš„ç ”ç©¶é¡å‹
4. **æœ€å¾Œçµ¦è‡¨åºŠå»ºè­°** â€” è¾¯è«–çš„ç›®çš„æ˜¯ç‚ºäº† Discussion section çš„å¯«ä½œ

---

## ç›¸é—œæŠ€èƒ½

- `concept-development` â€” åˆ†æ concept å¼±é»
- `draft-writing` â€” å°‡è¾¯è«–çµæœå¯«å…¥ Discussion
- `literature-review` â€” æ‰¾æ›´å¤šæ”¯æŒ/åå°çš„æ–‡ç»
